<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058968</url>
  </required_header>
  <id_info>
    <org_study_id>4097</org_study_id>
    <secondary_id>F1J-MC-HMAV</secondary_id>
    <nct_id>NCT00058968</nct_id>
  </id_info>
  <brief_title>A Study for the Treatment of Painful Diabetic Neuropathy</brief_title>
  <official_title>Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if duloxetine can help patients with painful
      diabetic neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol will assess the efficacy and safety of duloxetine. It will also look at how
      duloxetine affects quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in average pain severity as measured by an 11-point Likert scale.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain severity for worst pain and night pain as measured by an 11-point Likert scale.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity scale to measure severity of illness at the time of assessment.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement scale to measure the degree of improvement at the time of assessment.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory to measure the severity of pain.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Portion of the Short Form McGill pain questionnaire measures severity of 11 pain descriptors.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (17 item) used to assess severity of depression symptoms during the course of therapy.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic Allodynia measure to elicit the pain severity to a normally non-painful stimulus.</measure>
  </secondary_outcome>
  <enrollment>660</enrollment>
  <condition>Diabetic Neuropathy, Painful</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients at least 18 years of age.

          -  Patients with pain due to diabetic neuropathy in both legs.

          -  Females must not be pregnant or plan to become pregnant during the study.

          -  Stable Glycemic control.

          -  Average mean pain severity score of at least 4.0 as assessed by completion of a daily
             diary.

        Exclusion Criteria:

          -  You are related to or work for the physician conducting the study or are employed by
             Eli Lilly and Company.

          -  You have a severe or serious medical condition that causes you to be hospitalized
             often; or you have had a kidney transplant or are on current dialysis.

          -  You have participated in a study for an investigational drug within the last 30 days.

          -  You have a history of major depressive disorder, generalized anxiety disorder, or
             alcohol or eating disorders.

          -  You have a past medical history or diagnosis of mania, bipolar disorder, or psychosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLilly (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2003</study_first_submitted>
  <study_first_submitted_qc>April 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2003</study_first_posted>
  <last_update_submitted>May 16, 2007</last_update_submitted>
  <last_update_submitted_qc>May 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2007</last_update_posted>
  <keyword>neuropathy</keyword>
  <keyword>pain</keyword>
  <keyword>diabetes</keyword>
  <keyword>chronic pain</keyword>
  <keyword>persistent pain</keyword>
  <keyword>leg pain</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>foot pain</keyword>
  <keyword>painful neuropathy</keyword>
  <keyword>diabetic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

